Does State Medicaid Cover Dayvigo (Lemborexant)?

What Is Dayvigo and Why Does Medicaid Coverage Vary?

Dayvigo (lemborexant) is a dual orexin receptor antagonist approved by the FDA in December 2019 for adults with insomnia characterized by difficulty with sleep onset or maintenance [1]. Unlike benzodiazepines or Z-drugs, it blocks orexin OX1 and OX2 receptors rather than broadly depressing the central nervous system, which gives it a distinct safety profile [2]. Medicaid coverage decisions are made by each state independently under a framework called the Preferred Drug List (PDL). The federal Centers for Medicare and Medicaid Services sets minimum formulary standards, but states retain wide latitude on which branded sleep agents they cover.

The SUNRISE-1 trial (N=1,006, published in JAMA Network Open 2019) showed lemborexant 5 mg reduced subjective sleep-onset latency by 17.0 minutes and lemborexant 10 mg by 19.2 minutes versus placebo at the end of month 1, with benefits sustained to month 6 [3]. Because that clinical record is strong, coverage denials are almost always administrative rather than clinical: the state has not added the drug to its PDL, or has placed it on a non-preferred tier behind cheaper alternatives like generic zolpidem (which costs under $10 per month at most pharmacies).

The FDA label for lemborexant carries a Schedule IV controlled-substance designation, which adds a layer of scrutiny in some state Medicaid programs that apply stricter managed-care rules to scheduled drugs [1]. This scheduling decision does not reflect its abuse potential relative to traditional hypnotics; it is a regulatory category that states use when deciding PDL placement.

Which States Currently Cover Dayvigo on Medicaid?

Coverage changes quarterly, but as of mid-2025, fewer than half of state Medicaid programs include lemborexant on a covered or preferred tier without requiring an exception. States with active managed-care organizations (MCOs) handling their Medicaid pharmacy benefit often have more restrictive formularies than fee-for-service programs [4]. Checking your specific plan's PDL is the first concrete step, and the state Medicaid agency's website will have the current PDL document.

States that have historically covered other dual orexin receptor antagonists, such as suvorexant (Belsomra), are somewhat more likely to cover lemborexant as well, because the therapeutic class is already on their radar. The American Academy of Sleep Medicine's 2023 clinical practice guideline recommends DORAs as a treatment option for chronic insomnia, which some state Medicaid medical directors have cited when expanding coverage [5]. That guideline states: "We suggest the use of lemborexant for sleep onset and sleep maintenance insomnia in adults" with a weak-positive strength of evidence rating [5].

Three practical ways to find your state's current status are: (1) call the member services number on your Medicaid card, (2) log in to your state Medicaid beneficiary portal and search the formulary tool, or (3) ask the dispensing pharmacy to run a test claim before the prescription is filled. Option 3 takes about two minutes and gives you a real-time coverage determination rather than a PDL document that may be weeks out of date.

Prior Authorization Criteria: What Medicaid Programs Typically Require

Prior authorization (PA) for Dayvigo on Medicaid is the norm rather than the exception in states that cover it. Most PA criteria follow a similar pattern, though exact language differs [6]. A typical PA requirement includes a documented diagnosis of chronic insomnia disorder per DSM-5 criteria, a statement that the insomnia is not secondary to an untreated primary condition (e.g., uncontrolled sleep apnea), and evidence of at least one prior trial of a lower-cost agent.

The specific agents required in step therapy vary. Common first-line requirements include:

• Generic zolpidem immediate-release (10 mg or less) for a minimum of 14 to 30 days
• Generic doxepin 3 mg or 6 mg, which carries its own FDA indication for sleep maintenance insomnia [7]
• Cognitive behavioral therapy for insomnia (CBT-I), which the American College of Physicians recommends as the first-line treatment in its 2016 clinical practice guideline [8]

If your prescriber documents that zolpidem or doxepin is contraindicated, inappropriate due to drug interactions, or was previously trialed without adequate response, most PA reviewers will accept that as satisfying the step-therapy requirement without a new trial [6]. Examples that qualify include: a patient on opioids where zolpidem's CNS depression risk is unacceptable, or a patient with narrow-angle glaucoma where doxepin is contraindicated.

PA approvals, when granted, typically cover 6 to 12 months before renewal is required. Prescribers should document sleep diary data, Insomnia Severity Index scores, or actigraphy results in the chart to support renewal requests [9].

Step Therapy and the "Fail-First" Problem

Step therapy, sometimes called "fail-first" policy, requires patients to try and fail a cheaper drug before the insurer will pay for the intended drug. For Dayvigo on Medicaid, this almost always means a mandatory trial of generic zolpidem, and sometimes a second step through doxepin or eszopiclone before the PA reviewer will consider lemborexant [10].

The clinical problem with blanket step therapy for insomnia is that older agents carry real risks. Zolpidem is associated with next-morning impairment, particularly in women; the FDA issued a drug safety communication in 2013 reducing the recommended zolpidem dose for women to 5 mg because of this [11]. Benzodiazepines carry dependency and fall risk, particularly in older adults. The 2019 American Geriatrics Society Beers Criteria explicitly lists benzodiazepines and non-benzodiazepine hypnotics (Z-drugs) as potentially inappropriate medications in older adults, citing a 1.73-fold increased risk of motor vehicle accidents and a significant fall-related fracture association [12].

A prescriber can use these safety signals as clinical justification to skip step therapy. If the patient is over 65, or takes concomitant CNS depressants, documenting those facts in the PA request often satisfies the medical-necessity exception language that most state Medicaid PA criteria include. The key phrase to include in PA paperwork is "clinically contraindicated" rather than "preferred," because the former triggers a different review pathway in most MCO systems [6].

A 12-week open-label extension of the SUNRISE-1 data showed no clinically meaningful residual sleepiness or rebound insomnia after discontinuation, which is a useful evidence point when arguing against mandatory Z-drug trials on safety grounds [3].

How to Appeal a Dayvigo Medicaid Denial

Every Medicaid enrollee in the United States has a federally protected right to a fair hearing when a covered service or drug is denied. This right comes from 42 CFR Part 431, Subpart E, and must be exercised within 90 days of the denial notice in most states, though some states give only 30 or 60 days, so read the denial letter carefully [13].

The appeal process has two levels in most states:

Level 1: Internal appeal or reconsideration. The MCO or state agency reviews the denial internally. Submit this request within 60 days. Include a letter of medical necessity from the prescriber that specifically addresses why the denied step-therapy agents are clinically inappropriate for this patient. Attach the relevant guideline language, such as the AASM 2023 recommendation for DORAs [5], and any objective sleep data (Insomnia Severity Index scores, actigraphy) from the patient's record.

Level 2: State fair hearing. If the internal appeal fails, request a fair hearing with the state Medicaid agency. An administrative law judge presides. Studies of Medicaid managed care appeals show that enrollees who submit written evidence from their physician and cite clinical guidelines win approximately 40 to 45 percent of fair hearings for pharmacy denials [14]. That is not a trivial success rate. File promptly because most states require the fair hearing request within 90 days of the adverse internal-appeal decision.

During the appeal process, ask the prescriber to request a peer-to-peer review with the MCO's medical director. Many PA denials are reversed at the peer-to-peer stage before any formal appeal is necessary. This single step resolves a meaningful share of pharmacy denials without the paperwork burden of a full fair hearing [14].

Formulary Tier Placement and What It Means for Cost

When Dayvigo is covered by a state Medicaid plan, its formulary tier determines what the patient pays at the counter. Most state Medicaid programs use a 3-tier or 4-tier structure [4]:

• Tier 1 (preferred generics): Generic zolpidem, generic doxepin, generic trazodone. Patient cost often $0 to $3.
• Tier 2 (preferred brands or non-preferred generics): Some branded DORAs may land here. Patient cost $5 to $10.
• Tier 3 or non-preferred brands: Dayvigo, if covered at all, typically sits here. Patient cost $10 to $45 per month depending on the state's copay schedule.
• Non-covered: No benefit; patient pays full price.

For Medicaid enrollees below 100 percent of the federal poverty level, federal law caps cost-sharing at nominal amounts, currently defined as no more than $4 per prescription for non-preferred drugs [4]. That cap is protective but only applies if the drug is on the formulary at all. If Dayvigo is classified as non-covered, no cost-sharing cap applies and the patient faces the full $320 list price.

At $85 per month cash-pay (the current GoodRx-range average), paying out of pocket at a discount pharmacy may be less burdensome than navigating a complex PA process, particularly for patients with straightforward insomnia and no complicating comorbidities [15]. The decision should be made with the prescriber based on the patient's income, the MCO's specific PA burden, and likelihood of approval.

Can Medicaid Patients Use the Dayvigo Manufacturer Savings Card?

No. The Eisai manufacturer savings card and most branded pharmaceutical co-pay assistance programs explicitly exclude patients who are covered by any federal or state government health program, including Medicaid, Medicare, TRICARE, and VA benefits [16]. Using a co-pay card to reduce cost-sharing on a government program is considered a violation of the federal Anti-Kickback Statute under the Office of Inspector General's guidance, which is why manufacturers include this exclusion.

Medicaid patients who are denied Dayvigo coverage and cannot afford cash pay have two legitimate options:

1. Patient assistance programs (PAPs). Eisai's patient assistance program offers free or reduced-cost Dayvigo to uninsured or underinsured patients who meet income criteria. Income thresholds vary, and Medicaid status itself may make the patient ineligible for PAP if the drug is on formulary but in a high tier. Call Eisai's access line or visit NeedyMeds.org for current eligibility details.
2. Exception or formulary exception request. This is distinct from an appeal; it asks the MCO to cover a non-formulary drug for a specific patient based on medical necessity. The prescriber submits clinical documentation and the MCO decides within 72 hours for standard requests or 24 hours for expedited requests under federal managed care rules [13].

Telehealth Prescribing of Lemborexant Under Medicaid

As a Schedule IV controlled substance, lemborexant prescribing via telehealth is subject to DEA regulations. Under the DEA's 2023 proposed telehealth rules, prescribing Schedule IV substances via telemedicine requires either an in-person evaluation or a referral from a provider who has conducted an in-person evaluation [17]. Many states have added their own telehealth flexibility provisions for Medicaid beneficiaries, particularly post-COVID, but the federal floor on controlled-substance prescribing still applies.

A practical workaround for established insomnia patients seeking telehealth access: if the patient has an existing documented diagnosis and prior prescription history in their medical record, a telehealth provider who performs a synchronous audio-visual encounter and documents the clinical rationale can often prescribe lemborexant under the DEA's current enforcement discretion policies [17]. Patients should confirm their specific state's Medicaid telehealth rules with the prescriber's office before the appointment, since rules differ by state and have changed repeatedly since 2020.

Clinical Snapshot: Lemborexant Efficacy and Safety Data

Coverage decisions are easier to fight when the prescriber can cite specific efficacy data in PA paperwork. Here are the key numbers:

The SUNRISE-1 trial (N=1,006, JAMA Network Open, 2019) compared lemborexant 5 mg, lemborexant 10 mg, and zolpidem extended-release 6.25 mg against placebo over 30 nights [3]. Both lemborexant doses outperformed placebo on subjective sleep onset latency (sOSL) and wake after sleep onset (WASO). Lemborexant 10 mg outperformed zolpidem ER on WASO in the first half of the night (P<0.05) [3].

The SUNRISE-2 trial (N=949, published in Sleep Medicine, 2020) evaluated lemborexant 5 mg and 10 mg versus placebo over 12 months [18]. Lemborexant 5 mg produced a mean reduction in sOSL of 21.0 minutes and lemborexant 10 mg produced 21.5 minutes at month 6, sustained at month 12 [18]. No rebound insomnia or withdrawal symptoms were observed at discontinuation [18].

On safety, the most common adverse event across both trials was somnolence, reported in 7 percent of patients on lemborexant 5 mg and 10 percent on lemborexant 10 mg versus 1 percent for placebo [3][18]. Next-morning driving performance was measured objectively in a separate driving simulation study; lemborexant 10 mg showed transient impairment at 9 hours post-dose on night 1 but not on night 8, suggesting an adaptation effect [19]. These data are worth including in PA letters for patients in safety-sensitive occupations.

The FDA-approved dosing is 5 mg taken no more than once per night, within 30 minutes of going to bed, with at least 7 hours remaining before the planned awakening time. The dose may be increased to 10 mg if the 5 mg dose is tolerated but not sufficiently effective. The maximum dose is 10 mg per night [1].